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Systemic sclerosis (SSc) is an autoimmune disease which is associated with the 
development of organ fibrosis and vasculopathy (1).  Patients with severe, early diffuse 
cutaneous SSc and significant internal organ involvement have a mortality rate of 50% at 
five years (2).  There are many aspects of SSc that support the hypothesis that it is an 
autoimmune disease and might respond to immunosuppressive therapy (3-4).  
Immunosuppressive agents like cyclophosphamide have been investigated as 
treatment for SSc.  Cyclophosphamide can affect immune function by decreasing 
circulating B and T cells (5).  A retrospective, open, controlled study of 103 SSc patients 
with multiple cycles suggested improved survival (6). 
To date, the immunomodulatory effect of thymoglobulin is not fully understood 
but includes increased T-cell clearance from blood, modulation of T-cell activation, 
elimination of cytotoxic T-cell, and increased T regulatory cells.  In a pilot study, 
thymoglobulin was studied as single agent therapy (7).  Matteson et al (8) treated 10 
patients with ATGAM alone, at total dose of 10 mg/kg on 5 consecutive days; two 
patients having improvement. 
Our center initiated trials in high dose autologous transplantation 
immunosuppressive therapy (ASCT) as treatment for SSc (9).  There have been durable 
responses seen.  However, some patients had too many comorbidities or the disease had 
progressed to the point that they were no longer reasonable candidates for ASCT.  We 
wished to try a less intensive immunosuppressive approach in these patients.  At the time 
of initiation of this study, only very limited data existed on treating patients with 
intermediate doses of cyclophosphamide plus thymoglobulin.  In this letter, we describe 
the outcome of four patients treated with the combination. 
Patients were treated with cyclophosphamide 2.5 g/m2 IV on day 1 with mesna IV 
(total 2.5 g/m2, divided in three doses).  IV hydration was started 4 hours prior to 
cyclophosphamide (at 2-3 cc/kg/hour) and continued throughout the cyclophosphamide 
infusion and for 24 hours, thereafter.  Thymoglobulin at 0.5 mg/kg IV (based on adjusted 
ideal body weight) was given on day 2, 2 mg/kg on day 3, and 2.5 mg/kg/day on days 4-
6.  On the first day, thymoglobulin was infused over 8 hours and on the following days, it 
was infused over 6 hours, if tolerated.  Thymoglobulin was provided at no charge to the 
patient by Sangstat (now Genzyme).  Prior to each dose of thymoglobulin, premedication 
with methylpredinisone 2 mg/kg IV,  Benadryl 25-50 mg IV, and acetaminophen 650 mg 
po was given.  Patients with a history of chronic long-term prednisone use had steroids 
tapered slowly to prevent clinical manifestations of adrenal insufficiency.  If systolic or 
diastolic blood pressure increased by 10% over baseline, enalapril was started at a dose of 
2.5 mg daily and increased as needed.  Prophylactic antibiotics were given at absolute 
neutrophil count (ANC) < 500 cells/mm3 and for VZV.  CMV antigenemia monitoring 
was done.  Patients (3 men and 1 woman, age 42-52 years) had already received a median 
of 4 different regimens of therapy (range 1-5) before study treatment, were 26 months 
from initial diagnosis (range 22-35), and all had already failed to control disease with 
standard cyclophosphamide therapy.  Organ systems involved included skin (n=4) with 
modified Rodman skin score (MRSS) of 16, 17, 25, 29, cardiac (n=3), pulmonary (n=4) 
(with DLCO 40, 38, 31, 26%) and gastrointestinal (n=3). 
There were no CMV reactivations.  All three patients who completed therapy had 
evidence of coagulase-negative staphylococcal bacteria treated with vancomycin.  Non-
hematological toxicity included: grade 2 coagulopathy (n=1), hepatic (grade 2, n=1; 
grade 3, n=1), metabolic (grade 2, n=2), pain (grade 2, n=1), cardiac (grade 3, n=2).  One 
patient died of regimen-related toxicity second to anaphylaxis/cardiac pulmonary arrest.  
ANC ≥  500 cells/mm3 was reached on D1, 8, 10.  No patients received blood product 
transfusions.  No patients had platelet count < 20,000 cells/mm3; 2 patients never reached 
< 50,000.  Patients were hospitalized 6-10 days. 
All three patients who completed therapy had improvement in their MRSS by 35-
53%, and improvement in HAQ-Disability Index by 50-92%.  Pulmonary function 
remained stable in one patient and improved in the other two (FVC by 21-33%, FEV1 by 
14-32%, and DLCO by 29-31%). 
Two patients had initial responses for nearly one to 3 years but eventually died of 
cardiac events associated with life-threatening underlying pre-existing SSc-cardiac 
involvement; both had a history of previous episodes of arrthymias.  One patient remains 
in remission at 69 months, having required no additional therapy. 
Although this data is as yet purely anecdotal, this treatment combination appears 
encouraging and may signal greater response than monotherapy.  This combination of 
cyclophosphamide and thymoglobulin, though, cannot be considered curative, but it did 
give some durable responses after one course.  Caution should be used in giving this 
therapy to very ill individuals as there was one death associated with thymoglobulin.  
Given the marginal clinical reserve of these patients, there is little ability to compensate 
in life-threatening situations.  This combination may offer an alternative regimen for 
high-risk SSc patients with progressive disease, especially those who are not candidates 
for ASCT. 
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